SYS 6020
Alternative Names: SYS-6020Latest Information Update: 25 Nov 2024
Price :
$50 *
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies; RNA
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma; Myasthenia gravis; Systemic lupus erythematosus
Most Recent Events
- 25 Nov 2024 Preclinical trials in Multiple myeloma in China (Parenteral) prior to November 2024
- 25 Nov 2024 Preclinical trials in Myasthenia gravis in China (Parenteral) prior to November 2024
- 25 Nov 2024 Preclinical trials in Systemic lupus erythematosus in China (Parenteral) prior to November 2024